Published in Gut on January 01, 1985
A comparative pharmacokinetic study of conventional propranolol and long acting preparation of propranolol in patients with cirrhosis and normal controls. Br J Clin Pharmacol (1987) 0.84
A study of the relationship between serum bile acids and propranolol pharmacokinetics and pharmacodynamics in patients with liver cirrhosis and in healthy controls. PLoS One (2014) 0.78
Pharmacodynamic and pharmacokinetic study of propranolol in patients with cirrhosis and portal hypertension. Br J Clin Pharmacol (1989) 0.76
The Pharmacokinetics of Single Dose vs Steady-State Doses of Propranolol in Cirrhotic Malay Patients. Malays J Med Sci (2002) 0.75
Beta-blockers in the secondary prevention of gastrointestinal haemorrhage in well-compensated cirrhotics. A multicentre randomised controlled study. Drugs (1989) 0.75
Safety of propranolol in portal hypertension. Conventional and long acting formulations. Drugs (1989) 0.75
Transection of the oesophagus for bleeding oesophageal varices. Br J Surg (1973) 26.26
Propranolol for prevention of recurrent gastrointestinal bleeding in patients with cirrhosis: a controlled study. N Engl J Med (1981) 3.13
Increased plasma protein binding of propranolol and chlorpromazine mediated by disease-induced elevations of plasma alpha1 acid glycoprotein. N Engl J Med (1978) 2.68
The disposition of propranolol. 3. Decreased half-life and volume of distribution as a result of plasma binding in man, monkey, dog and rat. J Pharmacol Exp Ther (1973) 2.54
The disposition of propranolol. I. Elimination during oral absorption in man. Pharmacology (1972) 2.50
Propranolol--a medical treatment for portal hypertension? Lancet (1980) 2.27
Disposition of propranolol. V. Drug accumulation and steady-state concentrations during chronic oral administration in man. Clin Pharmacol Ther (1973) 2.24
Controlled trial of propranolol for the prevention of recurrent variceal hemorrhage in patients with cirrhosis. N Engl J Med (1983) 2.10
A study of factors influencing drug disposition in chronic liver disease, using the model drug (+)-propranolol. Br J Clin Pharmacol (1976) 1.87
Assessment of propranolol in angina pectoris. Clinical dose response curve and effect on electrocardiogram at rest and on exercise. Br Heart J (1971) 1.85
Plasma binding and the affinity of propranolol for a beta receptor in man. Clin Pharmacol Ther (1976) 1.62
Comparison of the efficacy and pharmacokinetics of conventional propranolol and a long acting preparation of propranolol. Br J Clin Pharmacol (1980) 1.55
Method for measuring cerebral dysfunction in patients with liver disease. Br Med J (1970) 1.50
High-pressure liquid chromatographic method for the simultaneous quantitative analysis of propranolol and 4-hydroxypropranolol in plasma. J Chromatogr (1978) 1.30
Contribution of the liver to overall elimination of propranolol. J Pharmacokinet Biopharm (1976) 1.16
Suppression of chronic ventricular arrhythmias with propranolol. Circulation (1979) 1.04
Intravenous propranolol in patients with inflammation. Br J Clin Pharmacol (1982) 1.02
Precipitation of hepatic encephalopathy by propranolol in cirrhosis. Br Med J (Clin Res Ed) (1983) 0.98
Health inequalities among British civil servants: the Whitehall II study. Lancet (1991) 24.79
Resistance to -adrenoceptor stimulants (a possible explanation for the rise in ashtma deaths). Br J Pharmacol (1971) 6.11
Genetics of adeno-associated virus: isolation and preliminary characterization of adeno-associated virus type 2 mutants. J Virol (1984) 5.89
Human hepatic stellate cell lines, LX-1 and LX-2: new tools for analysis of hepatic fibrosis. Gut (2005) 5.39
Mechanisms of spontaneous resolution of rat liver fibrosis. Hepatic stellate cell apoptosis and reduced hepatic expression of metalloproteinase inhibitors. J Clin Invest (1998) 5.27
Knowledge of and attitudes to medicines in the Southampton community. Br J Clin Pharmacol (1986) 3.85
Mutation of a tyrosine localization signal in the cytosolic tail of yeast Kex2 protease disrupts Golgi retention and results in default transport to the vacuole. Mol Biol Cell (1992) 3.49
Practolol in treatment of angina pectoris. A double-blind trial. Br Med J (1970) 3.43
The implementation of Tomorrow's Doctors. Med Educ (2002) 3.29
Prescription information leaflets: a pilot study in general practice. Br Med J (Clin Res Ed) (1983) 3.15
Evidence for specificity in the encapsidation of Sindbis virus RNAs. J Virol (1989) 2.91
Adverse drug reactions and secrecy. BMJ (1992) 2.89
The benefits of prescription information leaflets (1). Br J Clin Pharmacol (1989) 2.81
Hyperglobulinaemia in liver disease. Lancet (1973) 2.74
Bird-fancier's lung and jejunal villous atrophy. Lancet (1975) 2.71
Amoebiasis-a diagnostic problem in Great Britain. Br Med J (1966) 2.70
Australia antigen in acute and chronic liver disease. Lancet (1969) 2.65
The effect of intra-operative passive movement therapy on non-surgical site pain after breast reconstructive surgery: a preliminary study. Anaesthesia (2014) 2.62
Muscular dystrophy in an X; 1 translocation female suggests that Duchenne locus is on X chromosome short arm. J Med Genet (1979) 2.57
Community treatment of end-stage renal failure by dialysis and renal transplantation from cadaver donors. Lancet (1969) 2.53
A cell cycle-regulated bacterial DNA methyltransferase is essential for viability. Proc Natl Acad Sci U S A (1996) 2.52
Extracellular matrix degradation and the role of hepatic stellate cells. Semin Liver Dis (2001) 2.50
Bacterial and dietary antibodies in liver disease. Lancet (1972) 2.48
Activation of cultured rat hepatic lipocytes by Kupffer cell conditioned medium. Direct enhancement of matrix synthesis and stimulation of cell proliferation via induction of platelet-derived growth factor receptors. J Clin Invest (1989) 2.46
Autoantibodies to reticulin in patients with idiopathic steatorrhoea, coeliac disease, and Crohn's disease, and their relation to immunoglobulins and dietary antibodies. Lancet (1971) 2.45
Training in academic medicine: a way forward for the new millennium. A discussion document from the Academic Medicine Committee of the Royal College of Physicians. J R Coll Physicians Lond (1999) 2.42
A comparison of oral milrinone, digoxin, and their combination in the treatment of patients with chronic heart failure. N Engl J Med (1989) 2.40
DiOC6 staining reveals organelle structure and dynamics in living yeast cells. Cell Motil Cytoskeleton (1993) 2.39
12-month follow-up of yoga and bio-feedback in the management of hypertension. Lancet (1975) 2.36
Auto-immune reactions in ulcerative colitis. Gut (1966) 2.26
Gliotoxin stimulates the apoptosis of human and rat hepatic stellate cells and enhances the resolution of liver fibrosis in rats. Gastroenterology (2001) 2.25
Intravenously administered isoproterenol sulfate dose-response curves in man. Arch Intern Med (1972) 2.23
Opioid users' attitudes towards and use of NHS clinics, general practitioners and private doctors. Br J Addict (1986) 2.18
Trial of relaxation in reducing coronary risk: four year follow up. Br Med J (Clin Res Ed) (1985) 2.07
Ultrasound simulator for venous access. Emerg Med J (2008) 2.04
Apoptosis of hepatic stellate cells: involvement in resolution of biliary fibrosis and regulation by soluble growth factors. Gut (2001) 2.02
Resilience and resistance of a lake phosphorus cycle before and after food web manipulation. Am Nat (1992) 2.01
Absorption and metabolism of nicotine from cigarettes. Br Med J (1975) 2.01
Drug kinetics and hepatic blood flow. Clin Pharmacokinet (1980) 2.01
The first pass metabolism of nifedipine in man. Br J Clin Pharmacol (1984) 1.99
Prospective testing of a scoring system designed to improve case selection for upper gastrointestinal investigation. Gastroenterology (1986) 1.98
Tissue inhibitor of metalloproteinase-1 messenger RNA expression is enhanced relative to interstitial collagenase messenger RNA in experimental liver injury and fibrosis. Hepatology (1996) 1.91
Randomised controlled trial of yoga and bio-feedback in management of hypertension. Lancet (1975) 1.89
Assessment of selective beta-adrenoceptor blockade in man. Br J Pharmacol (1973) 1.85
Bottle feeding, early gastroenteritis, and inflammatory bowel disease. Br Med J (1979) 1.83
When immigrants are not migrants: counting arrivals of the foreign born using the U.S. census. Int Migr Rev (1998) 1.80
Persistent measles virus genome in autoimmune chronic active hepatitis. Lancet (1987) 1.79
Increased sensitivity to nitrazepam in old age. Br Med J (1977) 1.79
Expression of tissue inhibitor of metalloproteinases 1 and 2 is increased in fibrotic human liver. Gastroenterology (1996) 1.79
Clinical evaluation of indoramin, a new antihypertensive agent. Eur J Clin Pharmacol (1973) 1.78
The Brucella abortus CcrM DNA methyltransferase is essential for viability, and its overexpression attenuates intracellular replication in murine macrophages. J Bacteriol (2000) 1.75
Tamponade in Dressler's syndrome with immunological studies. Br Med J (1972) 1.72
Potent antiretroviral therapy of primary human immunodeficiency virus type 1 (HIV-1) infection: partial normalization of T lymphocyte subsets and limited reduction of HIV-1 DNA despite clearance of plasma viremia. J Infect Dis (1999) 1.70
Pathogenesis of liver fibrosis. Clin Sci (Lond) (1997) 1.68
Hemodynamic and gas exchange alterations during Intralipid infusion in patients with adult respiratory distress syndrome. Chest (1989) 1.66
Isolation and characterization of PEP3, a gene required for vacuolar biogenesis in Saccharomyces cerevisiae. Mol Cell Biol (1991) 1.66
Complementation between Sindbis viral RNAs produces infectious particles with a bipartite genome. Proc Natl Acad Sci U S A (1991) 1.64
Cardiovascular reflexes in Parkinsonism. Clin Sci (1971) 1.62
Human hepatic lipocytes synthesize tissue inhibitor of metalloproteinases-1. Implications for regulation of matrix degradation in liver. J Clin Invest (1992) 1.62
Clinical experience with use of ultrasound sphygmomanometer. Br Heart J (1975) 1.62
Sleep apnoea patients have more automobile accidents. Lancet (1987) 1.60
Structure-based thresholds of toxicological concern (TTC): guidance for application to substances present at low levels in the diet. Food Chem Toxicol (2004) 1.60
In vivo examination of membrane protein localization and degradation with green fluorescent protein. Proc Natl Acad Sci U S A (1996) 1.59
Raised antibody titres to measles and rubella viruses in chronic active hepatitis. Lancet (1972) 1.57
Problems in assessing beta-adrenoceptor antagonism in man. Br J Clin Pharmacol (1975) 1.54
Comparison of laryngeal mask and intubating laryngeal mask insertion by the naïve intubator. Br J Anaesth (2000) 1.52
Disorders of the long head of the biceps tendon. J Shoulder Elbow Surg (2000) 1.50
Naming of drugs: pass the epinephrine, please. BMJ (1996) 1.48
Controlled trial of biofeedback-aided behavioural methods in reducing mild hypertension. Br Med J (Clin Res Ed) (1981) 1.48
Physical activity: the evidence of benefit in the prevention of coronary heart disease. QJM (2003) 1.47
Relaxin inhibits effective collagen deposition by cultured hepatic stellate cells and decreases rat liver fibrosis in vivo. Gut (2001) 1.47
The benefits of prescription information leaflets (2). Br J Clin Pharmacol (1989) 1.46
Should patients with inflammatory bowel disease smoke? Br Med J (Clin Res Ed) (1984) 1.46
Controlled prospective study of the effect on liver function of multiple exposures to halothane. Lancet (1975) 1.46
Correlates of willingness to consider organ donation among blacks. Soc Sci Med (1990) 1.45
Use of ultrahigh frequency ventilation in patients with ARDS. A preliminary report. Chest (1993) 1.45
The effect of ageing on the hepatic clearance of propranolol. Br J Clin Pharmacol (1979) 1.45
Viral antibodies and autoantibodies in chronic liver disease. Gut (1974) 1.45
Absorption and disposition kinetics of cromolyn sodium and the influence of inhalation technique. J Pharmacol Exp Ther (1987) 1.45
The accuracy of ultrasound in the detection of fatty infiltration of the liver. Br J Radiol (1980) 1.44
Trial of combination of guanethidine and oxprenolol in hypertension. Br Med J (1976) 1.44
Reticulin antibodies in patients with coeliac disease and their relatives. Gut (1975) 1.42
Prescription information leaflets: a national survey. J R Soc Med (1990) 1.42
Required request for organ donation: moral, clinical, and legal problems. Hastings Cent Rep (1988) 1.42
Age-related changes in the pharmacokinetics and pharmacodynamics of nifedipine. Br J Clin Pharmacol (1988) 1.40
Heterozygous MZ alpha 1-antitrypsin deficiency in adults with chronic active hepatitis and cryptogenic cirrhosis. N Engl J Med (1981) 1.40
Factors associated with planned and unplanned nuptial births. N Z Med J (1978) 1.39
Physician manpower reform: an analysis of the effects of the COGME Fourth Report on internal medicine residency positions. Council on Graduate Medical Education. Am J Med (1994) 1.38
Corynebacterium parvum-elicited hepatic macrophages demonstrate enhanced respiratory burst activity compared with resident Kupffer cells in the rat. Gastroenterology (1986) 1.37
Unilateral sensorineural hearing loss after general anaesthesia. Anaesthesia (2008) 1.37
Histological evidence of carcinoma in a hepatic tumour associated with oral contraceptives. Br Med J (1975) 1.36
Increased expression of connective tissue growth factor in fibrotic human liver and in activated hepatic stellate cells. J Hepatol (2000) 1.34
Isolation and characterization of PEP5, a gene essential for vacuolar biogenesis in Saccharomyces cerevisiae. Genetics (1990) 1.34
Drug metabolism by the gastrointestinal mucosa. Clin Pharmacokinet (1981) 1.33
Acid hydrolases in monocytes from patients with inflammatory bowel disease, chronic liver disease, and rheumatoid arthritis. Lancet (1978) 1.33
Circulating and tissue eosinophils in ulcerative colitis. Am J Dig Dis (1966) 1.32
A follow-up study of patients with post-cricoid webs. Q J Med (1971) 1.31